BR112022004906A2 - Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas - Google Patents

Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas

Info

Publication number
BR112022004906A2
BR112022004906A2 BR112022004906A BR112022004906A BR112022004906A2 BR 112022004906 A2 BR112022004906 A2 BR 112022004906A2 BR 112022004906 A BR112022004906 A BR 112022004906A BR 112022004906 A BR112022004906 A BR 112022004906A BR 112022004906 A2 BR112022004906 A2 BR 112022004906A2
Authority
BR
Brazil
Prior art keywords
osteoarthritis
adenovirus
humans
treatment
expression system
Prior art date
Application number
BR112022004906A
Other languages
English (en)
Inventor
Kelley Scott
Senter Rebecca
Chabicovsky Monika
Walsh Martin Emily
Bodick Neil
Hong Won
Wang Kris
Douglas Mark
Derek Jackson John
Original Assignee
Pacira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Therapeutics Inc filed Critical Pacira Therapeutics Inc
Publication of BR112022004906A2 publication Critical patent/BR112022004906A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

DOSAGENS EFICAZES DE UM SISTEMA DE LIBERAÇÃO E EXPRESSÃO BIOLÓGICA À BASE DE ADENOVÍRUS PARA O USO NO TRATAMENTO DE OSTEOARTRITE EM HUMANOS, E COMPOSIÇÕES COMPREENDENDO AS MESMAS. A divulgação se refere a composições farmacêuticas e métodos de uso de composições farmacêuticas compreendendo dosagens eficazes de um sistema deliberação e expressão biológica à base de adenovírus para o uso no tratamento ou prevenção de osteoartrite em articulações de humanos ou mamíferos por expressão gênica induzível a longo prazo de antagonista do receptor de interleucina-1 de humanos ou mamíferos (IL-1Ra) em células sinoviais, compreendendo um vetor adenoviral dependente de auxiliar contendo uma sequência de ácido nucleico que codifica um antagonista do receptor de interleucina-1 de humanos ou mamíferos (IL-1Ra), repetições terminais invertidas à esquerda e direita (L ITR e R ITR), o sinal de empacotamento adenoviral e não viral e sequências stuffer de ácido nucleico não codificantes, em que a expressão do gene antagonista do receptor de interleucina-1 de humanos ou mamíferos (IL-1Ra) dentro de células sinoviais é regulada por um promotor sensível à inflamação.
BR112022004906A 2019-09-18 2020-09-18 Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas BR112022004906A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902041P 2019-09-18 2019-09-18
US202062966632P 2020-01-28 2020-01-28
PCT/US2020/051642 WO2021055860A1 (en) 2019-09-18 2020-09-18 Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same

Publications (1)

Publication Number Publication Date
BR112022004906A2 true BR112022004906A2 (pt) 2022-06-28

Family

ID=74884388

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004906A BR112022004906A2 (pt) 2019-09-18 2020-09-18 Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas

Country Status (6)

Country Link
US (1) US20220403415A1 (pt)
EP (1) EP4031192A4 (pt)
JP (1) JP2022548373A (pt)
CN (1) CN114616001A (pt)
BR (1) BR112022004906A2 (pt)
WO (1) WO2021055860A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4392138A1 (en) * 2021-08-24 2024-07-03 Pacira Therapeutics, Inc. Il-1ra gene therapy for intervertebral disc degeneration
WO2024182549A1 (en) 2023-03-02 2024-09-06 Pacira Therapeutics, Inc. Compositions and methods for improved adenoviral- based gene therapy utilizing corticosteroid treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534782T3 (es) * 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
ES2802878T3 (es) * 2013-01-25 2021-01-21 Baylor College Medicine Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores
US20150118187A1 (en) * 2013-10-24 2015-04-30 Medgenics Medical Israel Ltd. Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof

Also Published As

Publication number Publication date
WO2021055860A1 (en) 2021-03-25
US20220403415A1 (en) 2022-12-22
CN114616001A (zh) 2022-06-10
EP4031192A1 (en) 2022-07-27
JP2022548373A (ja) 2022-11-18
EP4031192A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
Yount et al. A novel role for viral-defective interfering particles in enhancing dendritic cell maturation
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
BR112022004906A2 (pt) Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas
Wei et al. Duck MDA5 functions in innate immunity against H5N1 highly pathogenic avian influenza virus infections
Jagger et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response
Wongthida et al. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling
Kulkarni et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity
Shibasaki et al. Peculiar monomeric interferon gammas, IFN γrel 1 and IFN γrel 2, in ginbuna crucian carp
Harding et al. Rationally designed influenza virus vaccines that are antigenically stable during growth in eggs
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
CA2861408C (en) Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
BR112021019256A2 (pt) Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados
Del Campo et al. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
Chua et al. Inactivated influenza vaccine that provides rapid, innate-immune-system-mediated protection and subsequent long-term adaptive immunity
MX2021004397A (es) Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
Liniger et al. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens
BR112018011777A2 (pt) composições de fenfluramina e métodos para o preparo das mesmas
Prabhu et al. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population
Gregory et al. Influenza lung injury: mechanisms and therapeutic opportunities
Feng et al. The atypical occurrence of two biotin protein ligases in Francisella novicida is due to distinct roles in virulence and biotin metabolism
Kim et al. Molecular characterization and immunological roles of avian IL-22 and its soluble receptor IL-22 binding protein
Daviet et al. Induction of Mx and PKR failed to protect chickens from H5N1 infection
Zohari et al. Differences in the ability to suppress interferon β production between allele A and allele B NS1 proteins from H10 influenza A viruses
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico